INDIA is among the top five easiest places to start a new business, a global consortium of over 500 researchers said on Thursday (10) in its latest report.
The Global Entrepreneurship Monitor (GEM) 2021/2022 report, unveiled at the Dubai Expo, puts India on top amongst low-income economies on different entrepreneurial framework conditions.
It gathered data via a survey of at least 2,000 respondents across each of 47 high, medium and low-income economies.
Some 83 per cent believe that there are good opportunities to start a business in their area – second globally and 86 per cent believe they have the skills and knowledge to start a business – fourth globally.
Besides, 54 per cent cite fear of failure as a reason for not planning to start a new business in the next three years, placing India second out of 47 in this list.
The GEM report put India on the top amongst low-income economies (according to GDP per capita) on different entrepreneurial framework conditions such as entrepreneurial finance, ease of access to finance and government policy and support.
However, the results indicated that entrepreneur sentiment of growth expectation was weak – with more than 80 per cent of Indian entrepreneurs reporting much lower growth expectations than last year.
Dr Sreevas Sahasranamam, one of eight authors of the GEM report, said: “The fact that over 80 per cent of respondents in India agreed that it is easy to start a business in the country, placing India amongst the top five economies globally, reflects an entrepreneurial ecosystem that has improved, thanks to government initiatives such as ‘Startup India' and ‘Make in India'.”
However, entrepreneurial intentions among the general population and growth expectations among entrepreneurs are still muted, the senior lecturer in entrepreneurship and innovation at the Hunter Centre for Entrepreneurship at the University of Strathclyde in Glasgow said.
“So, there is a need for cultural change around reducing the fear of failure amongst the general population, and support for scaling-up new ventures,” he said.
Dr Sunil Shukla, director-general of the Entrepreneurship Development Institute of India and GEM India national team leader, said: “Entrepreneurship has become a key factor for sustainable economic growth and has huge potential to create employment opportunities”.
“Developing an entrepreneurial mindset within the country has become a primary objective for governments and societies worldwide. In the Indian context and given its socio-economic challenges as well as its size and scope, a holistic approach to entrepreneurship development can bring transformational changes to the socio-economic landscape of the country,” he said.
The survey data found that more than 77 per cent of entrepreneurs are pursuing new opportunities due to the Covid-19 pandemic - placing India first out of 47.
This observation reiterates the findings of a report published last year by researchers from the University of Strathclyde and King's College London that found almost 60 per cent of entrepreneurs in India predict a long-term positive impact of Covid-19 on their businesses.
Sahasranamam said: “We observed a clear relationship between the level of national income and the share of start-ups in business services, such as professional services, communications, with this share typically being much higher in high-income than in low-income economies”.
“Thus, encouraging new start-ups in differentiated, knowledge-based high-value business services compared to consumer services may improve the development path of developing economies like India, paving a path to its $5 trillion economy ambition.
Globally, the GEM report found that in 15 out of these 47 economies, more than half of entrepreneurs agreed that the pandemic had led to new business opportunities.
In 2020, this had been the case for just nine out of 46 economies.
The GEM is a consortium of national teams, primarily associated with top academic institutions that carry out survey-based research on entrepreneurship around the world.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.